Full-dose azacitidine in 5 days versus 7 days with a weekend break in myelodysplastic syndromes: a retrospective cohort study

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders manifesting with morphologic abnormalities and cytopenias, affecting 3 to 4 people in 100,000 per year1 and carrying a sizable risk of progression to acute myeloid leukemia (AML). Standard risk stratification using the Revised International Prognostic Scoring System (IPSS-R) estimates the risk of evolution to AML and the expected survival, with impact in defining treatment goals and selecting therapeutic options. Lower- (IPSS-R ≤ 3.5) and higher-risk MDS (IPSS-R> 3.5) represent two distinct entities, since some patients in the first group may never need therapy, and patients in the second group have a median survival of 1.5 years.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research